Suppr超能文献

国际政策指导基因组测序中次生发现的选择、分析和临床管理:系统评价。

International policies guiding the selection, analysis, and clinical management of secondary findings from genomic sequencing: A systematic review.

机构信息

Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON, Canada.

Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

出版信息

Am J Hum Genet. 2024 Oct 3;111(10):2079-2093. doi: 10.1016/j.ajhg.2024.08.012. Epub 2024 Sep 18.

Abstract

Secondary findings (SFs) from genomic sequencing can have significant impacts on patient health, yet existing practices guiding their clinical investigation are inconsistent. We systematically reviewed existing SFs policies to identify variations and gaps in guidance. We cataloged and appraised international policies from academic databases (n = 5, inception-02/2022) and international human genetic societies (n = 64; inception-05/2022), across the continuum of SFs selection, analysis, and clinical management. We assessed quality using AGREE-II and interpreted results using qualitative description. Of the 63 SFs policies identified, most pertained to clinical management of SFs (98%; n = 62; primarily consent and disclosure), some guided SFs analysis (60%; n = 38), while fewer mentioned SFs selection (48%; n = 30). Overall, policies recommend (1) identifying clinically actionable, pathogenic variants with high positive predictive values for disease (selection), (2) bioinformatically filtering variants using evidence-informed gene lists (analysis), and (3) discussing with affected individuals the SFs identified, their penetrance, expressivity, medical implications, and management (clinical management). Best practices for SFs variant analysis, clinical validation, and follow-up (i.e., surveillance, treatment, etc.) were minimally described. Upon quality assessment, policies were highly rated for scope and clarity (median score, 69) but were limited by their rigor and applicability (median scores, 27 and 25). Our review represents a comprehensive international synthesis of policy guiding SFs across the continuum of selection, analysis, and clinical management. Our synthesis will help providers navigate critical decision points in SFs investigation, although significant work is needed to address gaps in SFs analysis, clinical validation, and follow-up processes and to support evidence-based practice.

摘要

二级发现(SFs)来自基因组测序可能对患者健康产生重大影响,但现有的指导其临床研究的实践并不一致。我们系统地回顾了现有的 SFs 政策,以确定指导意见中的差异和差距。我们对来自学术数据库的国际政策(n=5,2022 年 2 月成立)和国际人类遗传学会的国际政策(n=64;2022 年 5 月成立)进行了分类和评估,涵盖了 SFs 选择、分析和临床管理的连续体。我们使用 AGREE-II 评估质量,并使用定性描述解释结果。在所确定的 63 项 SFs 政策中,大多数涉及 SFs 的临床管理(98%;n=62;主要是同意和披露),一些指导 SFs 分析(60%;n=38),而较少提及 SFs 选择(48%;n=30)。总体而言,政策建议(1)识别具有高阳性预测值的临床可操作性、致病性变体疾病(选择),(2)使用基于证据的基因列表进行生物信息学过滤变体(分析),并(3)与受影响的个体讨论识别的 SFs、其外显率、表现度、医学意义和管理(临床管理)。SFs 变体分析、临床验证和随访(即监测、治疗等)的最佳实践描述甚少。经过质量评估,政策在范围和清晰度方面得分很高(中位数为 69),但在严格性和适用性方面得分较低(中位数分别为 27 和 25)。我们的综述代表了对选择、分析和临床管理连续体中 SFs 指导的全面国际综合。我们的综述将帮助提供者在 SFs 调查的关键决策点上进行导航,尽管需要做大量工作来解决 SFs 分析、临床验证和随访过程中的差距,并支持基于证据的实践。

相似文献

10
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.

本文引用的文献

9
Establishing the Medical Actionability of Genomic Variants.建立基因组变异的医学可操作性。
Annu Rev Genomics Hum Genet. 2022 Aug 31;23:173-192. doi: 10.1146/annurev-genom-111021-032401. Epub 2022 Apr 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验